Efficiency and optimisation, quality and precision will guide the activity of the plant, which will start with three production lines – already tested, validated and currently being approved by the regulatory authorities – at full capacity at the beginning of 2022, with the production of thyroid hormones at a rate that will generate 240 million therapeutic doses per year, while employing over 250 people for all on-site productions. Enrico Gasperotti, Head of IBSA Group’s production plants, explained: “COSMOS is not just a production facility; it’s innovation and state-of-the-art technology and production, combined with the great skills of the people who work there. Production lines are managed by automated and interconnected systems, in line with the latest industry 4.0 requirements; this will allow us to have precise control of the systems and processes, thus ensuring the highest quality standards of the drugs we produce, which translates into an even greater safety for patients”.
COSMOS and the CorPharma district have been conceived with the comfort of people in mind since the very beginning, because it is with this approach that IBSA spaces are created – in Switzerland, in Italy and in the rest of the world.
“Creating a space in which to live and work well means creating the conditions to improve productivity, the quality of work and the atmosphere, activating a virtuous circle which benefits everyone. This whole process is part of the evolution and growth of IBSA, a Company that did not stop despite the pandemic and, on the contrary, continued to create jobs, maintaining a positive hiring trend throughout the Group, which led to today’s over 2,000 employees”, concluded Virginio Cattaneo, Head of Human Resources, IBSA Group.